1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. NEKs

NEKs

NIMA–related Kinases; NIMA (never in mitosis gene a)-related Expressed Kinases

NIMA-related Kinases (NEKs) are a class of serine/threonine protein kinases ubiquitous in eukaryotic organisms. NEKs play pivotal roles in cell cycle regulation, including chromosome condensation, mitotic entry, centrosome duplication, and mitotic exit.
The NEK family comprises 11 members in humans (NEK1-NEK11). NEK family members are widely involved in key biological processes such as cell cycle regulation, ciliogenesis, and DNA damage repair, making them potential therapeutic targets for diseases.
Abnormal activation or mutations of NEKs are closely associated with cancers, genetic diseases, neurodegenerative diseases, and other conditions[1][2][3][4].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-103646
    CK7
    Inhibitor 99.72%
    CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.
    CK7
  • HY-174270
    NLRP3-IN-79
    Inhibitor 99.10%
    NLRP3-IN-79 is an orally active NLRP3 inhibitor. NLRP3-IN-79 inhibits NLRP3 inflammasome with an IC50 of 10.69 nM. NLRP3-IN-79 blocks NLRP3 inflammasome assembly by directly binding to NLRP3 and disrupting the NEK7-NLRP3 interaction. NLRP3-IN-79 can be used for the study of NLRP3-driven diseases model, including systemic inflammation, peritonitis, and colitis.
    NLRP3-IN-79
  • HY-W998347
    ABS-752 hydrochloride
    98.81%
    ABS-752 is an orally active prodrug of CRBN-modulating molecular glue targeting. ABS-752 can effectively degrade GSPT1. ABS-752 can degrade NEK7. ABS-752 does not form ternary complexes with CRBN and the neosubstrates. ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002. ABS-752 can be used for the study of hepatocellular carcinoma (HCC).
    ABS-752 hydrochloride
  • HY-176463
    Nek2/Hec1-IN-3
    Inhibitor 98.05%
    Nek2/Hec1-IN-3 (Compound 11-28) is a Hec1/Nek2 interaction inhibitor. Nek2/Hec1-IN-3 disrupts Nek2/Hec1 binding and can be used for research of neoplastic diseases.
    Nek2/Hec1-IN-3
  • HY-101030A
    MBM-17S
    Inhibitor
    MBM-17S is a potent NIMA-related kinase 2 (Nek2) inhibitor, with an IC50 of 3 nM. MBM-17S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-17S shows antitumor activities, and no obvious toxicity to mice.
    MBM-17S
  • HY-116423A
    JH295 hydrate
    99.0%
    JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint. JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    JH295 hydrate
  • HY-169933
    NEK7-IN-1
    Inhibitor
    NEK7-IN-1 (Compound I-15) is the inhibitor for NIMA-related kinase 7 NEK7 with IC50 <100 nM. NEK7-IN-1 inhibits the IL-1β release with IC50 <50 nM.
    NEK7-IN-1
  • HY-153749
    Nek2/Hec1-IN-2
    98.0%
    Nek2/Hec1-IN-2 (Compound 14) is an inhibitor of Nek2/Hec1. Nek2/Hec1-IN-2 inhibits cancer cell proliferation with IC50 >25 μM.
    Nek2/Hec1-IN-2
  • HY-137046
    Nek2-IN-4
    Nek2-IN-4 is a potent NEK2 inhibitor with an IC50 value of 15 nM. Nek2-IN-4 inhibits cell proliferation. Nek2-IN-4 has the potential for the research of pancreatic cancer.
    Nek2-IN-4
  • HY-101029A
    MBM-55S
    Inhibitor
    MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice.
    MBM-55S
  • HY-101030
    MBM-17
    Inhibitor
    MBM-17 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 3 nM. It effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice.
    MBM-17
  • HY-168737
    NEK7-IN-2
    Inhibitor
    NEK7-IN-2 (compound 23) is a potent inhibitor of NLRP3-NEK7 interaction. NEK7-IN-2 can enhance the thermal stability of NEK7 and regulatie NLRP3 inflammasome assembly. NEK7-IN-2 inhibits IL-1β releases.
    NEK7-IN-2
  • HY-117398
    HCI-2184
    Inhibitor
    HCI-2184 is a Nek2 inhibitor with an IC50 of 39.90 nM. HCI-2184 significantly increases the effectiveness of Bortezomib (HY-10227) in inhibiting proteasome activity.
    HCI-2184
  • HY-120356
    T-1101
    Inhibitor
    T-1101 (TAI-95) is an orally active inhibitor for mitose regulating highly expressed oncoprotein 1 (Hec1). T-1101 blocks the interaction between Hec1 and NEK2, exhibits cytotoxicity in human liver cancer cells with GI50 of 15-70 nM. T-1101 induces apoptosis in Huh-7. T-1101 exhibits antitumor efficacy in mouse models.
    T-1101
  • HY-175283
    ABT-002
    Degrader
    ABT-002 is a molecular glue degrader targeting GSPT1 and NEK7. ABT-002 is the active metabolite of ABS-752 (HY-W599279). ABT-002 is promising for research of hepatocellular carcinoma (HCC).
    ABT-002
  • HY-177433
    NEK7 degrader-4
    Degrader
    NEK7 degrader-4 is a NEK7 molecular glue degrader with a DC50 of 9  nM. NEK7 degrader-4 can be used for autoinflammatory and autoimmune disorders like multiple sclerosis, neurodegeneraive diseases like Alzheimer's disease and cardiovascular and melabolic disorders like pericarditis and Type 2 diabetes research.
    NEK7 degrader-4
  • HY-150046
    Nek2-IN-6
    Nek2-IN-6 (Compound 28e) is a potent never in mitosis (NIMA) related kinase 2 (Nek2) inhibitor.
    Nek2-IN-6
  • HY-111090
    GSK461364 analogue 1
    Inhibitor
    GSK461364 analogue 1 is a thiophene-based PLK1 inhibitor with a PLK1 IC50 of 2 nM and a PLK3 IC50 of 630 nM. GSK461364 analogue 1 also acts as an inhibitor of Nek2 kinase (IC50: 21 nM). GSK461364 analogue 1 has a solubility of ≥190 μM in pH 7.4 PBS and a human plasma protein binding rate of 91.5%. GSK461364 analogue 1 can be used in studies related to colon cancer, lung cancer, breast cancer and ovarian cancer.
    GSK461364 analogue 1
  • HY-177559
    NEK7 degrader-2
    Degrader
    NEK7 degrader-2 (Compound 25) is a NEK7 degrader. NEK7 degrader-2 shows dose-dependent NEK7 degradation ability in human PBMC-derived macrophages. NEK7 degrader-2 reduce the release level of pro-inflammatory cytokines IL-1β induced by NLRP3 inflammasome activation. NEK7 degrader-2 can be used for the study of inflammatory diseases.
    NEK7 degrader-2
  • HY-W599279
    ABS-752
    Degrader
    ABS-752 is a potent and orally active GSPT1 and NEK7 molecular glue degrader. ABS-752 shows cytotoxicity. ABS-752 decreases the protein expression of GSPT1 and SALL4, NEK7. ABS-752 is a prodrug activated by the monoamine oxidase, VAP-1, to an aldehyde intermediate and subsequently to the active molecule, ABT-002 (HY-175283). ABS-752 has the potential for the research of hepatocellular carcinoma.
    ABS-752

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.